This file is provided for reference purposes only. It was current when it was produced, but it is no longer maintained and may now be out of date. Persons with disabilities having difficulty accessing information may contact us
for assistance. For reliable, current information on this and other health topics, we recommend consulting the NIH Clinical Center at http://www.cc.nih.gov/
The Influenza Viruses and their Vaccines
Dr. Brian Murphy
Co-Chief, Laboratory of Infectious Diseases
National Institute of Allergy and Infectious Diseases
Oct. 30, 2001 7 pm
Auditorium NIH Clinical Center
Dr. Brian Murphy's research
interest is the development of vaccines for important human viral pathogens.
He focused first on respiratory viruses but is now also working on the mosquito-borne
dengue viruses that annually cause 50 to 100 million cases of dengue fever in
tropical and semitropical areas around the world. Based on 20 years of research
by Dr. Murphy's laboratory, a new live attenuated influenza virus vaccine is
now undergoing evaluation by the Food and Drug Administration for licensure.
This vaccine is an example of the lab's long-term commitment to the development
of vaccines for viruses, even those as complicated as the influenza A virus,
which undergoes frequent antigenic changes.
Dr. Murphy and his colleagues
also have developed live attenuated vaccines for the respiratory syncytial virus
and parainfluenza viruses that cause severe respiratory tract disease in small
children. Some candidate RSV and PIV vaccines are in clinical trials. In addition,
these researchers developed the monoclonal antibody that is the basis of a new
treatment to prevent severe RSV illness in premature infants and patients with
heart and lung disease.
Dr. Murphy received a B.A.
degree from Wesleyan University in Connecticut and a medical degree from the
University of Rochester in New York. After an internship at Stanford University
Medical Hospital, he came to NIH in 1970 as a Research Associate in the Laboratory
of Infectious Diseases at the National Institute of Allergy and Infectious Diseases.
In 1983, he became the head of the laboratory's Respiratory Viruses Section,
and this year he was appointed as Co-Chief of the Laboratory of Infectious Diseases.
During 28 years of service
in the U.S. Public Health Service, Dr. Murphy received three P.H.S. awards
a Commendation Medal in 1977, a Meritorious Service Medal in 1985, and an Outstanding
Service Medal in 1988. He also received the Federal Laboratory Consortium Award
on Technology Transfer for 1992.
As an invited speaker, Dr.
Murphy has spoken frequently on virology and vaccine development in the United
States and abroad. He has served as a consultant and meeting organizer for the
World Health Organization and on a wide range of scientific advisory boards
and committees. A member of several professional societies, Dr. Murphy also
is an editorial board member or reviewer for 15 journals and holds 6 patents.
for the Public home
The information on this page is archived and provided for reference purposes only.